(Paris:COX),
| Press Release | ||
| Nicox Provides First Half 2025 Financial Results | ||
October 23, 2025 – release at 7:30 am CET Nicox SA (Euronext Growth Paris: FR0013018124, ALCOX), an international ophthalmology company, today provided the financial results for Nicox SA (the “Company”) for the first half of 2025, as approved by the Board of Directors on October 22, 2025, and provided an update on key future milestones. “Our recent licensing payments, financing and careful cost control have positioned us with over 12 months of operational runway and the ability to repay all existing financial debts. In addition, NCX 470 marketing authorisation preparation and filing costs are taken on by our partners, who will also be responsible for the commercialisation of NCX 470 worldwide in the over $7 billion glaucoma market. This is a significant achievement for the Company, allowing us to move forward on a solid footing. Our double focus is now on both accompanying our partners in obtaining regulatory approval for NCX 470 and exploring future growth opportunities for the company.” said Gavin Spencer, Chief Executive Officer of Nicox. Key Future Milestones
Subsequent events The Company received license payments in August and September totalling EUR12.5 million relating to the signature of the NCX 470 license to Kowa and the Denali clinical trial results, in addition to EUR2 million related to the initiation of clinical trails on NCX 470 in Japan. Part of these payments has been used to reduce the Company's financial debt, which amounted to EUR7.4 million as of 30 September 2025 and which is expected to be fully repaid in 2026. First Half 2025 Financial Results for Nicox SA Revenue for the first half of 2025 was EUR1.5 million (consisting principally of license payments) versus EUR6.1 million (including EUR3.1 million of net royalty payments and a license payment of EUR3.0 million) for the first half of 2024. The decrease mainly reflects the sale of the VYZULTA royalty stream to Soleus in the second half of 2024. Operating expenses for the first half of 2025 were EUR6.8 million compared to EUR10.1 million for the first half of 2024. The decrease primarily reflects lower payroll expenses following the cost reductions initiated in 2024, and the end of Pfizer royalty payments after the sale of the VYZULTA royalties to Soleus. Net loss for the six months ended June 30, 2025 was EUR8.9 million, compared to a net loss of EUR4.3 million for the same period in 2024. The net loss for the first half of 2025 includes a EUR3.0 million foreign exchange loss on US dollar-denominated receivables and cash, versus an insignificant amount in 2024. As of June 30, 2025, Nicox SA had cash and cash equivalents of EUR5.7 million (excluding receipt of EUR12.5 million of license payments and partial debt repayment after the reporting period, as set out above) as compared with EUR10.5 million as of December 31, 2024. Based on the expected upcoming milestones and the repayment of all existing financial debts, the Company is financed for at least 12 months. The Company remains committed to cost control and optimizing resource allocation while maintaining the capabilities required to support our strategic objectives. If any of the assumptions around estimated income or costs change, this may impact the cash runway of the Company. As of June 30, 2025, Nicox SA had financial debt of EUR14.8 million as compared with EUR15.1 million as of December 31, 2024. Only the figure related to the cash position and the debt of Nicox SA as of December 31, 2024, is audited; all other figures in this press release are non-audited. |
||
| About Nicox | ||
| Nicox SA is an international ophthalmology company developing innovative solutions to help maintain vision and improve ocular health. Nicox's lead late-stage development program is NCX 470 (bimatoprost grenod), a novel nitric oxide-donating bimatoprost eye drop, for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension, licensed to Ocumension Therapeutics for the Chinese, Korean and Southeast Asian markets and to Kowa in the rest of the world. Nicox also has a preclinical research program on NCX 1728, a nitric oxide-donating phosphodiesterase-5 inhibitor, with Glaukos. Nicox's first product, VYZULTA(R) in glaucoma, licensed exclusively worldwide to Bausch + Lomb, is available commercially in the U.S. and over 15 other territories. Nicox generates revenue from ZERVIATE(R) in allergic conjunctivitis, licensed in multiple geographies, including to Harrow, Inc. in the U.S., and Ocumension Therapeutics in the Chinese and in the majority of Southeast Asian markets.
Nicox, headquartered in Sophia Antipolis, France, is listed on Euronext Growth Paris (Ticker symbol: ALCOX). For more information www.nicox.com |
||
| Analyst coverage | ||
|
H.C. Wainwright & Co Yi Chen New York, U.S. |
||
| The views expressed by analysts in their coverage of Nicox are those of the author and do not reflect the views of Nicox. Additionally, the information contained in their reports may not be correct or current. Nicox disavows any obligation to correct or to update the information contained in analyst reports. | ||
| Contacts | ||
| Nicox Gavin Spencer Chief Executive Officer T +33 (0)4 97 24 53 00 communications@nicox.com |
||
| Disclaimer | ||
| The information contained in this document may be modified without prior notice. This information includes forward-looking statements. Such forward-looking statements are not guarantees of future performance. These statements are based on current expectations or beliefs of the management of Nicox S.A. and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Nicox S.A. and its affiliates, directors, officers, employees, advisers or agents, do not undertake, nor do they have any obligation, to provide updates or to revise any forward-looking statements.
Risks factors which are likely to have a material effect on Nicox's business are presented in section 3 of the “Rapport Annuel 2024” and in section 4 of the “Rapport semestriel 2025″ which are available on Nicox's website (www.nicox.com). Finally, this press release may be drafted in the French and English languages. If both versions are interpreted differently, the French language version shall prevail. |
||
| Nicox S.A. Sundesk Sophia Antipolis, Batiment C, Emerald Square, Rue Evariste Galois, 06410 Biot, France T +33 (0)4 97 24 53 00 |
||
| Balance sheet | ||
| (in thousands of euros) | June 30, 2025 | December 31, 2024 |
| ASSETS | ||
| Intangible fixed assets | 10 | 13 |
| Tangible fixed assets | 9 | 11 |
| Financial fixed assets | 703 | 725 |
| FIXED ASSETS | 722 | 749 |
| Trade receivables and related accounts | 1,047 | 1,643 |
| Other receivables | 3,526 | 9,349 |
| Cash assets | 5,705 | 10,542 |
| Prepaid expenses | 1,796 | 1,515 |
| CURRENT ASSETS | 12,074 | 23,049 |
| Unrealized foreign exchange losses and valuation differences – Assets | 1,508 | 13 |
| Loan redemption premiums | 306 | 610 |
| TOTAL REGULARISATION ACCOUNTS | 1,814 | 623 |
| TOTAL ASSETS | 14,610 | 24,421 |
| LIABILITIES | ||
| Share Capital | 729 | 692 |
| Premiums related to share capital | 534,264 | 533,549 |
| Retained earnings | (530,828) | (508,438) |
| Net loss for the financial year | (8,948) | (22,390) |
| Total shareholders' equity | (4,783) | 3,413 |
| Provisions for liabilities | 1,509 | 13 |
| Provisions for charges | 280 | 268 |
| Total provisions for liabilities and charges | 1,789 | 281 |
| Loans and debts from lending institutions | 14,813 | 15,064 |
| Loans and other financial debts | 33 | 82 |
| Accounts payable and related accounts | 1,484 | 1,651 |
| Tax and social security debts | 414 | 603 |
| Deferred income | 852 | 735 |
| Total current liabilities | 17,596 | 18,135 |
| Unrealized exchange gains and valuation differences – Liabilities | 8 | 2,592 |
| TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY | 14,610 | 24,421 |
| Income Statement | ||
| (in thousands of euros) | June 30, 2025 | June 30, 2024 |
| Sales of services | 526 | 2 |
| Sales of finished products | 1,000 | 6,067 |
| REVENUE | 1,526 | 6,069 |
| Reversals of depreciation, amortization, provisions and transfers of expenses | – | 449 |
| Other income | 144 | 105 |
| TOTAL OPERATING INCOME | 1,670 | 6,623 |
| Other purchases and external charges | (5,795) | (6,853) |
| Taxes, duties and similar payments | (44) | (42) |
| Salaries and wages | (590) | (1,548) |
| Social security expenses | (253) | (412) |
| Amortization | (5) | (9) |
| Impairment and provisions | (12) | – |
| Other expenses | (124) | (1,247) |
| TOTAL OPERATING EXPENSES | (6,823) | (10,111) |
| OPERATING PROFIT (LOSS) | (5,153) | (3,488) |
| Other interest and similar income | 373 | 398 |
| Reversal of provisions, impairment losses and transfer of expenses | – | 13 |
| Foreign exchange gains | 46 | 23 |
| TOTAL FINANCIAL INCOME | 419 | 434 |
| Amortization, depreciation and financial provisions | (2,993) | (383) |
| Interest and similar expenses | (546) | (817) |
| Foreign exchange loss | (676) | – |
| TOTAL FINANCIAL EXPENSES | (4,215) | (1,200) |
| FINANCIAL PROFIT (LOSS) | (3,796) | (766) |
| PRE-TAX LOSS | (8,949) | (4,254) |
| Exceptional income from previous financial year | – | 3 |
| EXCEPTIONAL INCOME | – | 3 |
| Exceptional charges from previous fiscal year | – | (12) |
| EXCEPTIONAL EXPENSES | – | (12) |
| EXCEPTIONAL INCOME (LOSS) | – | (9) |
| Research Tax credit | – | – |
| NET PROFIT & LOSS | (8,949) | (4,263) |
Attachment
